Age-specific Incidence of Systemic Lupus Erythematosus Epidemiologic estimates on SLE diagnosis are limited. The CDC National Lupus Registry network of population-based SLE registries has assessed and reported age-specific incidence of SLE by sex, race, and ethnicity. https://t.co/g5A7DMQIyp

Phase 1/2 COMPARE trial of CD19 CAR-T Rx in 6 ACPA+ RA pts w/ severe refractory Dz; after lymphodepletion, given mivocabtagene autoleucel (miv-cel), followed < 52wks. All had CRS, No ICANSs or serious AEs. All had CD19 cell depletion & Decr in AutoAbs. Efficacy: 3/6 had ACR70 & https://t.co/qfSdq2g0rk

Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB

Does exercise affect inflammatory biomarkers? Metanalysis of 61 studies shows mostly low certainty evidence of inflammation-modulating effects of exercise. In most chronic diseases, exercise showed anti-inflammatory trends w/ reductions in CRP, IL-6, TNF-α https://t.co/EP74b3mVAT https://t.co/WBTHjsCzKL

Spyre Therapeutics topline results of its anti-TL1A Ab (SPY072) in RA (n 133) sub-study: Phase 2 SKYWAY 12wk trial showed 2 doses SPY072 were signif better vs PBO for ACR20 (63% & 58% vs 43%), ACR50 (31% &38% vs 19%), DAS28-CRP reductions (-1.5 & -1.9 vs -1.3). TL1A inhib are https://t.co/S6gapB21uq

Ivarmacitinib (AKA SHR-0302) is a JAK1 inhib approved in China. Phase II/III RCT (NCT04481139) in active #AS Rx w/ ivarmacitinib 4 mg (n 187) or placebo (n 186) showing IVRMA @wk 12 IVRMA had signif better ASAS20 response(49% vs 29%) & ASAS40 (32% vs 18%). Also superior: total https://t.co/ilVtrQgHxR

🔥 Still’s Disease Awareness Day 2026 🐉 I Won’t Be Still: Making Still’s Disease Visible Show us a moment from your life with Still’s Disease. 📸 Share a photo/video + what “I Won’t Be Still” means to you. For 47 hours, let’s make Still’s visible. #MyStills #StillsDay https://t.co/B7VNmlIOQj

CAR-T Reality Check! The hype is outrunning the evidence, which now lives in a handy dashboard created and presented by Dr. Mike Putman @EBRheum. There are almost as many studies as there are CAR-T treated patients. Few numbers, limited F/U - Yet everyone is gaga about CAR-T. https://t.co/aCtA8il2fD

🆕 #AutoInflammatory / Periodic Fever Syndromes In Memory of Dr. Dan Kastner🕊️ So grateful Dr. Kastner agreed to review this graphic >1 year ago, providing thoughtful input and suggestions to improve the final version 🙏 New Board Review Series for Rheum OnePagers 📟 #RheumX https://t.co/zx8dX2yHkA

Registry Data Shows Liver Risk With Avacopan A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from https://t.co/nHF6RVpq2Z

Glucocorticoids: Use vs.Toxicity This review article addresses the recognition, prevention and management of GC toxicity in rheumatic patients. Despite guidelines and recommendations that GC be tapered, lowered or discontinued, they continue to be widely used with serious https://t.co/rmjoYJzCLD

Rheum Scholarship (8.21.2026) Dr. Cush reviews the news and journal articles from this past week on RheumNow; talking about lumbar belts, scholarships and misdiagnosis. https://t.co/T6uggKb8n7 https://t.co/HJCMQqghaE

39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower https://t.co/vflarmwSyv

402 RA pts w. symptomatic Extra-articular manifestations (eg, neuropathy, KCS) had significant impairment in quality of life and work productivity, independent of disease activity. They had lower HAQ (0.92 vs 0.68) & more Absenteeism https://t.co/1FH9gyxoxK https://t.co/faToGXpdSQ

A Tribute to Thomas A. Medsger Jr., MD (1936–2026) The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89. https://t.co/GGC3pZVfJp https://t.co/n0ckoeQ3ZX